Pura Vida Investments, Llc - Apr 5, 2023 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
10%+ Owner
Signature
/s/ Efrem Kamen, Managing Member of Pura Vida Investments, LLC
Stock symbol
OCX
Transactions as of
Apr 5, 2023
Transactions value $
$200,027
Form type
4
Date filed
4/7/2023, 05:12 PM
Previous filing
Apr 18, 2023
Next filing
Apr 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCX Common Stock Purchase $200K +663K +8.93% $0.30 8.09M Apr 5, 2023 By Pura Vida Master Fund, Ltd. F1, F2
holding OCX Common Stock 4.59M Apr 5, 2023 By the Managed Accounts. F1, F2
holding OCX Common Stock 768K Apr 5, 2023 By Pura Vida X Fund LP F1, F2
holding OCX Common Stock 1.38M Apr 5, 2023 By the Retirement Trust F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts" and collectively, the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI.
F2 By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any.